Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feb. 15, Vol. 25, No. 4

    • Feature Articles

      • Manufacturing Biologicals Effectively
      • Increasing cost pressures on the biotech industry, in particular, mean that scaleup doggedly remains a major stumbling block in bioprocess manufacturing. "Because of the high risks of clinical failure, large-scale process trials are often done ... more »
      • Personalized Arthritis Therapy
      • Recent reports of an increased risk of heart attack with the Cox-2 inhibiting drugs Vioxx and Celebrex have resulted in a huge setback for arthritis therapeutics. These drugs had become staples for the treatment of osteoarthritis (OA) and rheumatoid ... more »
      • Staying Up-to-Date in Biomarker Research
      • Costs associated with populating the drug pipeline are, as always, on the rise. Success demands that pharmaceutical research be linked to the biology of the human system as closely as possible and as soon as possible in the candidate-selection proce ... more »
      • What it Costs fo Operate a Biotech Facility
      • A new corporate location study compares the cost of doing business for the biotechnology industry in a series of 50 U.S., Canadian, and European cities. The study, prepared by the Princeton, NJ-based site selection firm, The Boyd Co., focuses on all ... more »
    • Wall Street BioBeat

      • Conservative Outlook Seen at Investor Forum
      • Biotech investors, executives, and entrepreneurs have always made it a priority to gather at the beginning of each year in San Francisco to conduct business at the “JP Morgan Healthcare Conference,” formerly the “Hambrecht & Quist Life Science I ... more »
    • FDA News and Analysis

      • FDA's Draft Guidance on Pharmacogenomics
      • Pharmacogenomics is said to have been created with the 1955 presentation of re-search relating excretory levels of isoniazid to therapeutic results (Frueh & Gurwitz; 2004). In the fifty years since then, the number of published articles referenc ... more »

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »